The Research Institute of the Vall d'Hebron Hospital (VHIR) in Barcelona has participated in a study, published in the New England Journal of Medicine, which shows that adding Sotagliflozine, an oral drug, to the usual treatment with insulin in patients with diabetes type diabetesI improve disease control in 28 percent of cases.
In addition, this analysis, presented at the LIII Annual Congress of the European Association for the Study of Diabetes held in the Portuguese City of Lisbon, confirms that in the group of patients treated with cabeglyphlozine, the glycosylated hemoglobin figure (HBA1C) was reduced0.46 percent, weight loss was 2.98 kg, blood pressure decreased among those suffered from 3.5 mmHg hypertension and the daily insulin dose was significantly reduced.
On the other hand, VHIR researchers indicate in their study that the incidence of severe hypoglycemia episodes was significantly lower compared to the placebo group;Instead, cases of diabetic ketoacidosis were superior.
For the head of the Research Group in Diabetes and Metabolism of this entity, Dr. Rafael Simón, “The study is of remarkable importance, since it will improve metabolic control, without increasing the dose of insulin or increasing the weight, in a segmentimportant of patients suffering from type I diabetes, and therefore, the risk of long -term complications will be lower. ”
